Slide 1: Fourth Quarter & Full Year 2025 Financial Results
Fourth Quarter & Full Year 2025 Financial Results February 26, 2026
Slide 2: Disclaimer
Disclaimer Numerical figures in the presentation have been subject to rounding adjustments. Accordingly, numerical figures shown as totals in various tables may not be arithmetic aggregations of the figures that precede them. In addition, unless otherwise indicated, references to the “Company,” “Cer
Slide 3: Financial Highlights: Fourth Quarter 2025
Financial Highlights Fourth Quarter 2025 REVENUE NET INCOME ADJ. EBITDA(2) DILUTED EPS ADJUSTED DILUTED EPS(3) $103.6M ($5.9M) $32.5M ($0.04) $0.09 3% GAAP YoY change PY $6.6M (3%) YoY PY $0.04 PY $0.15 2% CC YoY change (1) change (1) See Appendix for reconciliation of GAAP revenue to constant curre
Slide 4: Financial Highlights: Fiscal Year 2025
Financial Highlights Fiscal Year 2025 REVENUE NET INCOME ADJ. EBITDA(2) DILUTED EPS ADJUSTED DILUTED EPS(3) $418.8M ($1.6M) $134.5M ($0.01) $0.44 9% GAAP YoY change PY ($12.1M) 10% YoY PY ($0.08) PY $0.45 8% CC YoY change (1) change (1) See Appendix for reconciliation of GAAP revenue to constant cur
Slide 5: 4Q 2025 Results - Revenue
4Q 2025 Results - Revenue GAAP Reported Revenue Constant Currency Revenue(1) ($Millions) ($Millions) 100.4 103.6 100.4 102.6 58.1 57.3 58.1 56.9 42.3 46.4 42.3 45.7 4 4Q 2024 4 4Q 2025 4Q 2024 4Q 2025 Software Services Software Services Certara reported 2% constant currency(1) revenue growth 5 (1) S
Slide 6: FY 2025 Results - Revenue
FY 2025 Results - Revenue GAAP Reported Revenue Constant Currency Revenue(1) ($Millions) ($Millions) 418.8 416.0 385.1 385.1 235.6 234.2 229.5 229.5 155.7 183.3 155.7 181.8 FY 2024 FY 2025 FY 2024 FY 2025 Software Services Software Services Certara reported 8% constant currency(1) revenue growth 6 (
Slide 7: 4Q 2025 and TTM Results - Net Bookings
4Q 2025 and TTM Results - Net Bookings 4Q Reported Net Bookings TTM Reported Net Bookings ($Millions) ($Millions) 144.5 155.2 445.3 482.1 84.8 99.1 297.7 275.9 59.7 56.1 184.3 169.4 4Q 2024 4Q 2025 4Q 2024 4Q 2025 Software Services Software Services Trailing twelve months bookings are highly correla
Slide 8: Historical TTM Book to Bill
Historical TTM Book to Bill ($Millions) 1.16x 1.16x 1.16x 1.13x 1.15x $485 $465 $445 $425 $405 $385 $365 $345 $325 $305 $285 $265 482.1 $245 445.3 457.7 470.8 471.4 $225 405.8 415.6 418.8 $205 385.1 394.5 $185 $165 $145 $125 $105 $85 $65 $45 $25 4Q 2024 1Q 2025 2Q 2025 3Q 2025 4Q 2025 TTM Bookings T
Slide 9: Historical Software Net Retention Rate (NRR)
Historical Software Net Retention Rate (NRR)(1) 115.0% 114.1% 110.0% 108.6% 108.0% 107.6% 107.6% 107.2% 105.5% 105.0% 103.9% 102.4% 100.0% 4Q 2023 1Q 2024 2Q 2024 3Q 2024 4Q 2024 1Q 2025 2Q 2025 3Q 2025 4Q 2025 NRR(1) provides insight into growth and retention among existing software customers (1) O
Slide 10: 4Q & FY 2025 Results – Adjusted EBITDA
4Q & FY 2025 Results – Adjusted EBITDA 4Q Adjusted EBITDA(1) FY Adjusted EBITDA(1) ($Millions) ($Millions) 33.5 32.5 134.5 122.0 4Q 2024 4Q 2025 FY 2024 FY 2025 Adjusted EBITDA 33% 31% 32% 32% Margin(1) 4Q25 Adjusted EBITDA declined (3%) vs. the prior year period FY25 Adjusted EBITDA grew 10% vs. th
Slide 11: FY 2025 Results – Reconciliation of Revenue & Bookings Growth
FY 2025 Results – Reconciliation of Revenue & Bookings Growth FY 2025 Revenue FY 2025 Bookings Item Growth Contribution Item Growth Contribution Organic Software(1) +7% Organic Software(1) +1% + Chemaxon ~1080 bps + Chemaxon ~790 bps Reported Software +18% Reported Software +9% Organic Services(1) +
Slide 12: 4Q25 Business Updates
4Q25 Business Updates Key Takeaways from Fourth Quarter and January 2026: Appointed Jon Resnick as CEO 4Q Performance Near-Term Objectives to Effective January 1st, 2026 Consistent with Plan Improve Business Performance • Resnick brings over 30 years of • Total revenue was in-line with • Focused str
Slide 13: 4Q25 Bookings YoY Trends – Pharma/Biotech Customers
4Q25 Bookings YoY Trends – Pharma/Biotech Customers Tier1 Software Bookings | (6%) y/y Services Bookings | +17% y/y I Slowness due to customer reprioritization, Growth driven by strength in regulatory, slower trial completions, pipeline conversion offset by biosimulation II Growth driven by further
Slide 14: 2026 Outlook
2026 Outlook Initiating FY 2026 guidance Key Assumptions 2025 Guidance REVENUE GROWTH ADJUSTED ADJUSTED EBITDA MARGIN(1) DILUTED EPS(1) 0-4% 30-32% $0.44-$0.48 Reported revenue growth of 0-4% Fully diluted shares expected to be in the range of 160-162M This financial guidance is provided as of Febru
Slide 15: Appendix
Appendix CERTARAQ
Slide 16: Reconciliation of Net Income (Loss) to Adjusted EBITDA
Reconciliation of Net Income (Loss) to Adjusted EBITDA THREE MONTHS ENDED TWELVE MONTHS ENDED DECEMBER 31, DECEMBER 31, 2025 2024 2025 2024 (in thousands) Net income (loss)(a) $ (5,895) $ 6,577 $ (1,595) $ (12,051) Interest expense(a) 5,119 5,004 19,738 21,520 Interest income(a) (1,565) (1,365) (5,7
Slide 17: Reconciliation of Net Income (Loss) to Adjusted Net Income (Loss)
Reconciliation of Net Income (Loss) to Adjusted Net Income (Loss) THREE MONTHS ENDED TWELVE MONTHS ENDED DECEMBER 31, DECEMBER 31, 2025 2024 2025 2024 ( in thousands) Net income (loss) (a) $ (5,895) $ 6,577 $ (1,595) $ (12,051) Currency (gain) loss(a) 282 (182) (891) 2,344 Equity-based compensation
Slide 18: Reconciliation of Diluted EPS to Adjusted Diluted EPS
Reconciliation of Diluted Earnings Per Share to Adjusted Diluted Earnings Per Share THREE MONTHS ENDED TWELVE MONTHS ENDED DECEMBER 31, DECEMBER 31, 2025 2024 2025 2024 Net income (loss) (a) $ (0.04) $ 0.04 $ (0.01) $ (0.08) Currency (gain) loss(a) - - (0.01) 0.02 Equity-based compensation expense(b
Slide 19: Reconciliation of Revenues to Revenues Adjusted for Constant Currency
Reconciliation of Revenues to the Revenues Adjusted for Constant Currency THREE MONTHS ENDED DECEMBER 31, Change 2025 2025 2024 $ % $ % Actual CC Actual Actual Actual CC Impact (GAAP) (non-GAAP) (GAAP) (GAAP) (GAAP) (non-GAAP) (non-GAAP) (in thousands except percentage) Revenue Software $ 46,381 $ 4
Slide 20: Notes to Reconciliations
Notes to Reconciliations a) Represents a measure determined under GAAP. b) Represents expense related to equity-based compensation. Equity-based compensation has been, and will continue to be for the foreseeable future, a recurring expense in our business and an important part of our compensation st
Slide 21: Accelerating Medicines, Together
Accelerating Medicines, Together